Galaxy Biomedical Investment Co., Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 478.483 million compared to CNY 578.842 million a year ago. Operating loss was CNY 115.900 million compared to CNY 136.950 million a year ago. Net loss was CNY 108.374 million compared to CNY 116.376 million a year ago. Basic loss per share from continuing operations was CNY 0.0985 compared to CNY 0.1058 a year ago.